Business Description
Medivir AB
NAICS : 325412
ISIN : SE0020181014
Share Class Description:
LTS:0GP7: Ordinary SharesDescription
Medivir AB develops drugs with a focus on cancers where there are medical needs. The company invests in indication areas where available treatment methods are limited or lacking and there are opportunities to offer significant improvements to patients. Medivir focuses on the development of MIV-818, a prodrug that has been designed to provide a targeted anti-tumor effect in the liver while minimizing any side effects. Birinapant, a SMAC mimetic, has been out-licensed for development in combination with IGM antibodies for the treatment of solid tumors.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 12.52 | |||||
| Equity-to-Asset | 0.76 | |||||
| Debt-to-Equity | 0.06 | |||||
| Debt-to-EBITDA | -0.16 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -1.14 | |||||
| Beneish M-Score | -2.16 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -31.1 | |||||
| 3-Year EBITDA Growth Rate | -10.8 | |||||
| 3-Year EPS without NRI Growth Rate | -7.3 | |||||
| 3-Year FCF Growth Rate | 16.1 | |||||
| 3-Year Book Growth Rate | -19.1 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.05 | |||||
| Quick Ratio | 3.05 | |||||
| Cash Ratio | 2.89 | |||||
| Days Sales Outstanding | 272.53 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -42.5 | |||||
| Shareholder Yield % | 0.58 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1211.06 | |||||
| Net Margin % | -1170.06 | |||||
| FCF Margin % | -1018.43 | |||||
| ROE % | -52.11 | |||||
| ROA % | -40.08 | |||||
| ROIC % | -63.77 | |||||
| ROC (Joel Greenblatt) % | -647.83 | |||||
| ROCE % | -47.94 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shiller PE Ratio | 2.17 | |||||
| PS Ratio | 34.27 | |||||
| PB Ratio | 1.46 | |||||
| Price-to-Tangible-Book | 2.63 | |||||
| EV-to-EBIT | -2.11 | |||||
| EV-to-EBITDA | -2.18 | |||||
| EV-to-Revenue | 24.33 | |||||
| EV-to-FCF | -3.1 | |||||
| Price-to-Median-PS-Value | 1.49 | |||||
| Price-to-Net-Current-Asset-Value | 2.9 | |||||
| Price-to-Net-Cash | 3.21 | |||||
| Earnings Yield (Greenblatt) % | -47.39 | |||||
| FCF Yield % | -17.52 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers